Physician profile
Robert John O'Brian
NPI 1730140724
$1,192.62
in general payments reported to CMS, 2019-2025
12 companies · $51.33 in 2025
The $51.33 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $183 · 2021: $259 · 2022: $516 · 2023: $136 · 2024: $47.67 · 2025: $51.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $234.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $239.54 | 2022-2025 | |
| Janssen Biotech, INC. | $214.64 | 2020-2024 | Simponi Aria, Tremfya |
| Amgen INC. | $205.87 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $137.64 | 2020-2023 | Orencia |
| Horizon Therapeutics Plc | $107.66 | 2020-2022 | |
| Ucb, INC. | $89.62 | 2020-2022 | |
| Pfizer INC. | $47.63 | 2022 | |
| Lilly USA, LLC | $43.57 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $38.90 | 2022 | |
| Mallinckrodt Hospital Products INC. | $28.68 | 2022 | |
| Aurinia Pharma U.S., INC. | $22.13 | 2022 | |
| Organon LLC | $16.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert O'Brian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.